New Delhi, June 3 (UNI) Biocon Pharma Limited, a biopharmaceutical firm, on Tuesday said that drug regulator, Drugs Controller General of India under the CDSCO (Central Drugs Standard Control Organisation) has given nod to its liraglutide drug for Indian market.



The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.



Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, termed the approval for liraglutide, as a step forward in expanding access of this product to patients suffering from diabetes.



“The approval enables us to address a critical need by making this drug available, and aligns with Biocon’s mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India.’’

Liraglutide is administered as a once-daily injection and was approved by the US FDA in 2019 for the treatment of children who are ten years or older with type 2 diabetes, making it the first non-insulin drug approved to treat type 2 diabetes in children, said the release.



According to various reports, India has an estimated 77 million people above 18 years old living with diabetes (type 2) and nearly 25 million with pre-diabetes. It is the second-highest country in the world for diabetes prevalence after China.

UNI AJ PRS